Of the cancer types with 10 or more representative samples, mTOR-pathway activation was most prevalent in HR+ breast-cancer samples (59/61; 97%) and triple-negative (absence of estrogen and progesterone receptors and the absence of HER2 overexpression) breast-cancer samples (26/27, 96%); mTOR-pathway activation was least prevalent in hepatocellular-carcinoma samples (9/16; 56%) and colorectal-cancer samples (44/71; 62%). This evidence concerns the gene PGR and colorectal cancer.